Shattuck Labs to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
March 09 2022 - 8:21AM
Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage
biotechnology company pioneering the development of bi-functional
fusion proteins as a new class of biologic medicine for the
treatment of patients with cancer and autoimmune disease, today
announced that two posters have been accepted for presentation at
the American Association for Cancer Research (AACR) Annual Meeting,
which is being held April 8-13, 2022 at the Ernest N. Morial
Convention Center in New Orleans, Louisiana. The first poster will
highlight preclinical data from the company’s GADLEN™ platform,
while the second will highlight preclinical data from SL-9258
(TIGIT-Fc-LIGHT), derived from the company’s ARC® platform,
demonstrating its ability to broaden the activity of checkpoint
inhibitors through targeted myeloid cell and effector lymphocyte
activation.
Presentation Details
Title: Bispecific gamma delta T cell engagers containing
butyrophilin 2A1/3A1 heterodimeric fusion protein efficiently
activate Vg9Vd2 T cells and promote tumor cell killingPresenter:
Dr. Anne Lai, Ph.D., Principal Scientist, ShattuckSession:
Immunology - Immunomodulatory Agents and Interventions 2 Date/Time:
Tuesday, April 12, 2022, 1:30 p.m. to 5:00 p.m. ETLocation: New
Orleans Convention Center, Exhibit Halls D-H, Poster Section
37Abstract Number: 3514
Title: LIGHT (TNFSF14) costimulation with TIGIT blockade
broadens the activity of checkpoint inhibitors (CPIs) into CPI
refractory and resistant tumors through targeted myeloid cell and
effector lymphocyte activationPresenters: Dr. George Fromm, Ph.D.,
Vice President of Research and Development, Shattuck, and Kyung Jin
Yoo, Research Associate, ShattuckSession: Immunology - Combination
Immunotherapies 2 Date/Time: Wednesday, April 13, 2022, 9:00 a.m.
to 12:30 p.m. ETLocation: New Orleans Convention Center, Exhibit
Halls D-H, Poster Section 37Abstract Number: 4214
Additional meeting information can be found on the AACR website,
https://www.aacr.org. The posters will be available under the
Events & Presentations section of the Company’s website shortly
after the event.
About Shattuck Labs, Inc.Shattuck Labs,
Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company
pioneering the development of bi-functional fusion proteins as a
new class of biologic medicine for the treatment of patients with
cancer and autoimmune disease. Compounds derived from Shattuck’s
proprietary Agonist Redirected Checkpoint, ARC®, platform
simultaneously inhibit checkpoint molecules and activate
costimulatory molecules within a single therapeutic. The company’s
SL-172154 (SIRPα-Fc-CD40L) program, which is designed to block the
CD47 immune checkpoint and simultaneously agonize the CD40 pathway,
is being evaluated in two Phase 1 trials. A second product
candidate, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase
1 trial in solid tumors or lymphomas. Additionally, the company is
advancing a proprietary Gamma Delta T Cell Engager, GADLEN™,
platform, which is designed to bridge gamma delta T cells to tumor
antigens for the treatment of patients with cancer. Shattuck has
offices in both Austin, Texas and Durham, North
Carolina. For more information, please
visit: www.ShattuckLabs.com.
Investor Contact:Conor RichardsonSenior
Director, Finance & Investor RelationsShattuck Labs,
Inc.InvestorRelations@shattucklabs.com
Media Contact:Stephanie AscherManaging
DirectorStern Investor Relations,
Inc.Stephanie.ascher@sternir.com
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shattuck Labs (NASDAQ:STTK)
Historical Stock Chart
From Jul 2023 to Jul 2024